New
HealthMore in Health →
Entrada’s Next-Generation Duchenne Therapy Stumbles in Early Study
Entrada Therapeutics’ next-generation Duchenne muscular dystrophy candidate disappointed in an early study, a setback in a competitive race to improve exon-skipping drugs.
Key Takeaways
- STAT News reported that Entrada’s next-generation Duchenne therapy disappointed in an early study.
- The candidate is part of the exon-skipping drug race in Duchenne muscular dystrophy.
DE
DT Editorial AI··via statnews.com